However, BGP-15, a poly (ADP-ribose) polymerase (PARP) inhibitor and insulin sensitizer [71], is a potential therapeutic agent for AD as it mitigates these impairments in memory and learning via attenuating the aforementioned impairments caused by acetylation of tau at K274 and K281 [70, 72]. The gene discussed is MAPT; the disease is Alzheimer disease.